drugset / Trial / NCT00562120

A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

NCT00562120 ↗

Phase 2 Completed 21 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

An H3 receptor antagonist should reduce the congestion associated with allergic rhinitis. A nasal allergen challenge will be given to patients to induce rhinitis symptoms and acoustic rhinometry will be used to measure the congestion.

Timeline

Start
2007-12
Primary completion
2008-08
Completion
2008-08

Outcome

Missed primary endpoint

registry analysis (superiority or other test); PF-03654746 10 mg vs Placebo; p = 0.302; ANOVA; NCT00562120 ↗

registry analysis (superiority or other test); PF-03654746 1 mg vs Placebo; p = 0.229; ANOVA; NCT00562120 ↗

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allegra-D Unknown — Oral
Comparator Fexofenadine Unknown — Oral
Subject PF-03654746 Small molecule — Oral

Indications